Novel therapeutic strategies in infection and cancer management

Current Aging Science

Volumn 5, Issue 3, 2012, Pages 218-224

  Clayton, Paul ^a  

^a Institute of Food Brain and Behaviour   (United Kingdom)

Author keywords

1 3; 1 6 beta glucans; Antibiotic; CR 3; Cyanogen; Furanone; Hypothiocyanite; Lactoperoxidase; Resistance; Type B malnutrition

Indexed keywords

ADHESIN; ANTIBIOTIC AGENT; BACTERIOCIN; BETA 1,3 GLUCAN; BETA 1,6 GLUCAN; CHEMOKINE RECEPTOR CCR3; DEFENSIN; FUCOIDIN; FURANONE DERIVATIVE; LACTOFERRIN; LACTOPEROXIDASE; LYSOZYME; TOLL LIKE RECEPTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL TRANSMISSION; CANCER CONTROL; CHRONIC STRESS; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RESISTANCE; INNATE IMMUNITY; MALNUTRITION; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUORUM SENSING; RECEPTOR BINDING; RESPIRATORY TRACT INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84874846622     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811205030008     Document Type: Article

References (115)

1. World Health Organisation. Prevention of hospital-acquired infections: a practical guide. Available at http://www.who.int/csr/re-sources/publications/drugresist/whocdscsreph200212.pdf. Accessed March 23, 2006.
2. National Audit Office (UK). Management and Control of Hospital-Acquired Infection in Acute NHS Trusts in England. 17th February 2000.
3. Plowman R, Graves N, Griffin MA, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialities of a district general hospital in England and the national burden imposed. J Hosp Infect 2001: 47; 198-209
4. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86.
5. Wenzel RP. The antibiotic pipeline-challenges, costs and values. N Engl J Med 2004: 351; 523-26.
6. Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China-a major future challenge. Lancet 2009; 373(9657): 30.
7. Poste G. 2005. http://www.biodesign.asu.edu/news/Biodesign-Institute-Director-George-Poste-Named-Scientist-Of-The-Year.
8. Health Protection Agency (UK). Trends in Antimicrobial Resistance in England and Wales. December 2005.
9. Woodford N, Reddy S, Fagan EJ, et al. Wide geographic spread of diverse acquired AmpC-lactamases in Escherichia coli and Klebsiella spp. in the UK and Ireland. J Antimicrob Chemother 2007; 59(1): 102-5.
10. Nunn P. http://www.iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/Nunn.ashx
11. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005; 13(10): 491-6.
12. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008; 11(5): 393-400.
13. Gallagher-Allred CR, Voss AC, Finn SC, McCamish MA. Malnutrition and clinical outcomes: the case for medical nutrition therapy. J Am Diet Assoc 1996; 96(4): 361-6.
14. Naber TH, Schermer T, de Bree A, et al. Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. Am J Clin Nutr 1997; 66(5): 1232-9.
15. Bistrian BR, Blackburn GL, Vitale J, Cochran D, Naylor J. Prevalence of malnutrition in general medical patients. JAMA 1976; 235(15): 1567-70.
16. Daly JM, Hearne B, Dunaj J, et al. Nutritional rehabilitation- patients with advanced head and neck cancer receiving radiation therapy. Am J Surg 1984; 148: 514-20.
17. Andrassy RJ, DuBois T, Page CP, Patterson RS, Paredes A. Early postoperative nutritional enhancement utilizing enteral branchedchain amino acids by way of a needle catheter jejunostomy. Am J Surg 1985; 150: 730-34.
18. Fietkau R. Principles of feeding cancer patients via enteral or parenteral nutrition during radiotherapy. Strahlentherapie Onkologie 1998; 174: 47-51.
19. Edington J, Winter PD, Coles SJ, Gale CR, Martyn CN. Outcomes of undernutrition in patients in the community with cancer or cardiovascular disease. Proc Nutr Soc 1999; 58(3): 655-61.
20. Chandra RK. Influence of multinutrient supplement on immune responses and infection-related illness in 50-65 year old individuals. Nutr Res 2002; 22: 5-11.
21. Bogden J. Daily micronutrient supplements enhance delayedhypersensitivity skin test responses in older people. Am J Clin Nutr. 1994; 60: 437-47.
22. Jain AL. Influence of vitamins and trace-elements on the incidence of respiratory infection in the elderly. Nutr Res 2002; 22: 85-7.
23. Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. J Am Med Assoc 1997; 277: 1380-6.
24. Czop JK, Austen KF. A-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol 1985; 134: 2588-93.
25. Kernodle DS, Gates H, Kaiser AB. Prophylactic anti-infective activity of poly-[1-6]-D-glucopyranosyl-[1-3]-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother 1998; 42: 545-9.
26. Wakshull E, Brunke-Reese D, Lindermuth J. PGG-glucan, a soluble-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology 1999; 41: 89-107.
27. LeBlanc BW, Albina JE, Reichner JS. The effect of PGG-glucan on neutrophil chemotaxis in vivo. J Leukoc Biol. 2006; 79(4): 667-75.
28. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3bopsonized target cells. J Clin Invest 1996; 98(1): 50-61.
29. Yan J, Vetvicka V, Xia A, et al. Beta-glucan, a specific biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999; 163(6): 3045-52.
30. Underhill DM. Macrophage recognition of zymosan particles. J Endotoxin Res 2003;9(3): 176-80.
31. Goodridge HS, Simmons RM, Underhill DM. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol 2007; 178(5): 3107-15.
32. van Bruggen R, Drewniak A, Jansen M, et al. Complement receptor 3, not dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. Mol Immunol 2009; 47(2-3): 575-81.
33. Kankkunen P, Teirilä L, Rintahaka J, Alenius H, Wolff H, Matikainen S. (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol 2010; 184(11): 6335-42.
34. Rasmussen LT, Fandrem Jr, Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta-1, 3-D-polyglucose derivatives. Scand J Immunol 2985; 63:73-80.
35. Rasmussen LT, Konopski Z, Oian P, Seljelid R. Killing of Escherichia coli by mononuclear phagocytes and neutrophils stimulated in vitro with-1, 3-D-polyglucose derivatives. Microbiol Immunol 1992; 36(11): 1173-88.
36. Mansell PWA, Ichinose I-I, Reed RJ, Krements ET, McNamee RB, Di Luzio NR. Macrophage-mediated destruction of human malignant cells in vivo. J Nat Cancer Inst 1975; 54: 571-80.
37. Hahn MG, Albersheim P: Host-pathogen interactions. XIV. Isolation and partial characterization of an elicitor from yeast extract. Plant Physiol 1978; 62: 107.
38. Robertsen B, Engstad RE, Jorgensen JB. Beta-glucans as immunostimulants in fish. In: Stolen, JS, Fletcher, TC (Eds.), Modulators of Fish Immune Responses. SOS Publication, Fair Haven, NJ, USA, Vol. 1, pp. 83-99.
39. Song Y-L, Hsieh Y-T. Immunostimulation of tiger shrimp hemocytes for generation of microbicidal substances: analysis of reactive oxygen species. In Developmental and Comparative Immunology 1994; 18(3): 201-09.
40. Williams DL, Cook JA, Hoffmann EO, Di Luzio NR. Protective effect of glucan in experimentally induced candidiasis. J Reticuloendothel Soc 1978; 23: 479-90.
41. Williams DL, Diluzio NR. Glucan induced modification of experimental Staphylococcus aureus infection in normal, leukemic and immunosuppressed mice. Adv Exp Med Biol 1979; 121(A): 291-306.
42. Williams DL, Diluzio NR. Glucan-induced modification of murine viral hepatitis. Science 1980; 208: 67-9.
43. Leibovich SJ, Danon D. Promotion of wound repair in mice by application of glucan. J Reticuloendothelial Soc 1980; 27: 1-11.
44. Lahnborg G, Hedstrom KG, Nord CE. The effect of glucan-a host resistance activator-and ampicillin on experimental intraabdominal sepsis. J Reticuloendothelial Soc 1982; 32: 347-53.
45. Williams DL, Diluzio NR. Modification of experimental viral hepatitis by glucan-induced macrophage activation. In The Reticuloendothelial System and Pathogenesis of Liver Disease. Liehr and Grun, eds. Amsterdam: Elsevier/North Holland Biomedical Press 1983. pp. 363-8.
46. Onderdonk AB, Cisneros RL, Hinkson P, Ostroff G. Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo. Infect Immun 1992; 60(4): 1642-7.
47. Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129(11): 1204-10.
48. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220(5): 601-9.
49. Dellinger EP, Babineau TJ, et al. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch Surg 1999; 134(9): 977-83.
50. Kournikakis B, Mandeville R, Brousseau P., Ostroff G Anthraxprotective effects of yeast beta 1, 3 glucans. Med Gen Med 2003 21; 5(1): 1.
51. Mandeville R: Biophage Pharma Inc. Data on file, 2004.
52. Jung K, Ha Y, Ha SK, et al. Antiviral effect of Saccharomyces cerevisiae beta-glucan to swine influenza virus by increased production of interferon-gamma and nitric oxide. J Vet Med B Infect Dis Vet Public Health 2004; 51(2): 72-6.
53. Tzianabos AO, Cisneros RL. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann NY Acad Sci 1996; 797: 285-7.
54. Gerson CJ, Sabater M, Scuri A, et al. The lactoperoxidase system functions in bacterial clearance of airways. Am J Respir Cell Mol Biol 2000; 22:665-71.
55. Karaolu A, Aydin F, Kilic SS, Kilic AO. Antimicrobial activity and characteristics of bacteriocins produced by vaginal lactobacilli. Turk J Med Sci 2003; 33: 7-13.
56. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-60.
57. Murakami M, Ohtake T, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002; 81(12): 845-50.
58. Pruitt KM. The salivary peroxidase system: thermodynamic, kinetic and antibacterial properties. J Oral Pathol 1987; 16: 417-20.
59. Ratner AJ, Prince A. Lactoperoxidase: new recognition of an old enzyme in airway defenses. Am J Respir Cell Mol Biol 2000; 22(6): 642-4.
60. Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R, et al. Lactoperoxidase and human airway host defense. W.H.O. 164 & 204. Am J Respir Cell Mol Biol 2003; 29(2): 206-12.
61. Pruitt KM & Reiter B. Biochemistry of the Peroxidase System. In Pruitt KM and Tenuovo JO (Eds) The Lactoperoxidase System; Chemical, biological significance. New York Marcel Dekker 1985, 143-178.
62. de Wit JN, van Hooijdonk CCM. Structure, function and applications of lactoperoxidase in natural antimicrobial systems. Netherlands Milk Dairy J. 1996; 50: 227-44.
63. Wang H, Ye X, Ng TB. First demonstration of an inhibitory activity of milk proteins against human immunodeficiency virus-1 reverse transcriptase and the effect of succinylation. Life Sci 2000; 67(22): 2745-52.
64. Van Hooikdonk ACM, Kussendrager KD, Steijns JM. 2000. In vivo antimicrobial and antiviral activity of components in bovine milk and colostrums involved in non-specific defence. Br J Nut 2000: S127-134.
65. Seifu E, Buys EM, Donkin EF. Significance of the lactoperoxidase system in the dairy industry and its potential applications: a review. Trends in Food Sci Technol 2003; 16: 137-54.
66. Fweja LW, Lewis MJ, Grandison AS. Challenge testing the lactoperoxidase system against a range of bacteria using different activation agents. J Dairy Sci 2008; 91(7): 2566-74.
67. Reiter B, Marshall VM, Bjorck L, Rosen CG. Nonspecificbactericidal activity of the lactoperoxidases-thiocyanate-hydrogen peroxide system of milk against Escherichia coli and some gramnegative pathogens. Infect Immunol 1976; 13: 800-7.
68. Shin K, Tomita M, Lonnerdal B. Identification of lactoperoxidase in mature human milk. J Nutr Biochem 2000; 11: 94-102.
69. Reiter B, Perraudin J-P. Lactoperoxidase: biological functions. In Peroxidases in Chemistry and Biology, Vol. I. J. Everse, K. E. Everse, and MB Grisham (editors). Boca Raton, FL CRC Press, 2000, pp. 144-80
70. Slungaard A, Mahoney JR Jr. Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. Implications for cytotoxicity. J Biol Chem. 1991; 266(8): 4903-10
71. Thomas EL, Aune TM. Lactoperoxidase, peroxide, thiocyanate antimicrobial system: correlation of sulfhydryl oxidation with antimicrobial action. Infect Immun. 1978; 20(2): 456-63.
72. Mangold CM, Streeck RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol. 1993; 67(8): 4588-97.
73. Almeida JD, Bradburne AF, Wreghitt TG. The effect of sodium thiocyanate on virus structure. J Med Virology 1979. 4(4): 269-77.
74. Hinton WL. The economics of fruit and vegetable conservation. Prog Food Nutr Sci. 1980; 4(3-4): 111-21.
75. Li B, Allendorf DJ, Hansen R, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 2006; 177(3): 1661-9.
76. Nawoor Z, Burns R, Smith DF, Sheehan S, O'Herlihy C, Smyth PP. Iodine intake in pregnancy in Ireland--a cause for concern? Ir J Med Sci 2006; 175(2): 21-4.
77. FAO/WHO Technical Report 2005. Benefits and Potential Risks of the Lactoperoxidase System of Raw Milk Preservation. Report of a FAO/WHO technical meeting, Rome, Nov-Dec '05
78. Oram JD, Reiter B. The inhibition of streptococci by lactoperoxidase, thiocyanate and hydrogen peroxide. The oxidation of thiocyanate and the nature of the inhibitory compound. Biochem J. 1966; 100(2): 382-8.
79. Leyer GJ, Johnson EA. Acid adaptation induces cross-protection against environmental stresses in Salmonella typhimurium. Appl Environ Microbiol. 1993; 59(6): 1842-7.
80. Borgers D, Junge B. Thiocyanate as an indicator of tobacco smoking. Prev. Med 1979; 8: 351-7.
81. Medizinische und biologische Bedeutung der thiocyanate (Rhodanide) Veb Verlag Volk (1982) Ed. W.Weuffen (Berlin).
82. Newell DG, Koopmans M, Verhoef L, et al. Food-borne diseases the challenges of 20 years ago still persist while new ones continue to emerge. Int J Food Microbiol 2010; 139 Suppl 1:S3-15.
83. Menezes SM, Cordeiro LN, Viana GS. Punica granatum (pomegranate) extract is active against dental plaque. J Herb Pharmacother 2006; 6(2): 79-92.
84. Weiss EI, Kozlovsky A, Steinberg D, et al. A high molecular mass cranberry constituent reduces mutans streptococci level in saliva and inhibits in vitro adhesion to hydroxyapatite. FEMS Microbiol Lett 2004; 232(1): 89-92
85. Yamanaka A, Kimizuka R, Kato T, Okuda K. Inhibitory effects of cranberry juice on attachment of oral streptococci and biofilm formation. Oral Microbiol Immunol 2004; 19(3): 150-4.
86. Saeki Y. Effect of seaweed extracts on Streptococcus sobrinus adsorption to saliva-coated hydroxyapatite. Bull Tokyo Dent Coll. 1994; 35(1): 9-15.
87. Saeki Y, Kato T, Naito Y, Takazoe I, Okuda K. Inhibitory effects of funoran on the adherence and colonization of mutans streptococci. Caries Res 1996; 30(2): 119-25.
88. Wiklund S. Personal communication, 2007
89. Martinelli D, Grossmann G, Séquin U, Brandl H, Bachofen R. Effects of natural and chemically synthesized furanones on quorum sensing in Chromobacterium violaceum. BMC Microbiol 2004; 4: 25.
90. Choo JH, Rukayadi Y, Hwang JK. Inhibition of bacterial quorum sensing by vanilla extract. Lett Appl Microbiol 2006; 42(6): 637-41.
91. Vattem DA, Mihalik K, Crixell SH, McLean RJ. Dietary phytochemicals as quorum sensing inhibitors. Fitoterapia. 2007; 78(4): 302-10.
92. Clayton P, Rowbotham J. How the mid-Victorians worked, ate and died. Int J Environ Res Public Health 2009; 6(3): 1235-53.
93. Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol. 2005 Jun 1; 174(11): 7050-6.
94. Aloia J, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect 2007, 135(7):1095-1096
95. Chandra RK. Graying of the immune system: can nutrient supplements improve immunity in the elderly? J Am Med Assn 1997; 277:1398-1399.
96. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 1992; 340:1124-1127.
97. Clayton P, Rowbotham J. An Unsuitable and Degraded Diet? Part III: Victorian Consumption Patterns and Their Health Benefits. Journal of the Royal Society of Medicine (2008c).101:454-462
98. Cohen ML 1992. Epidemiology of drug resistance: implications for a post anti-microbial era. Science 257:1050-5
99. Czop JK, Puglisi AV, Miorandi DZ, Austen KF. Perturbation of beta- glucan receptors on human neutrophils initiates phagocytosis and leukotriene B4 production. J Immunol 1988; 141:3170-6.
100. de Felippe Junior J, da Rocha e Silva Jr. M, Maciel FM, Soares A, Mendes NF: Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surgery, Gynecology and Obstetrics 1993; 177(4): 383-388.
101. Di Luzio NR, Williams DL: The role of glucan in the prevention and modification of microparasitic diseases. In: Assessments of chemical regulation of immunity in veterinary medicine. Gainer JH, ed. NY: Scientific, Medical and Scholarly Pub., 1983;
102. Di Renzo L, Yefenof E, Klein E. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18). Eur J Immunol 1991; 21:1755-8.
103. Fisher H, 2009. Mechanism and Function of DUOX in the Epithelia of the Lung. Antioxidants and Redox Signalling 11(10):1-14
104. Gerber G. Personal communication, 2006, and internal data provided by Fibona AG.
105. Gross C. P; Sepkowitz K. A. The myth of the medical breakthrough: Smallpox, vaccination, and Jenner reconsidered. Int J Infect. Dis.1998, 3 (1), pp.54-60
106. Hughes DA, Wright AJ, Finglas PM, et al. The effect of betacarotene supplementation on the immune function of blood monocytes from healthy male nonsmokers. J Lab Clin Med 1997; 129:309-17.
107. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S and Hussell T. A Critical Role for OX40 in T Cell-mediated Immunopathology during Lung Viral Infection, J Exp Med 198 (8) 1237-1242
108. Kiermeier F, Kuhlman H, Thiocyanate forms and doseage. Münch. Med. Wochenschr. (1972)
109. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial peptides in the airway. Curr Top Microbiol Immunol. 2006;306:153-82. Review
110. Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan J. Combined Yeast {beta}-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55. Cancer Res. 2007 Aug 1;67(15):7421-7430.
111. Li M, Eastman CJ, Waite KV, Ma G, Zacharin MR, Topliss DJ, Harding PE, Walsh JP, Ward LC, Mortimer RH, Mackenzie EJ, Byth K, Doyle Z. Are Australian children iodine deficient? Results of the Australian National Iodine Nutrition Study. Med J Aust. 2006 Feb 20; 184(4):165-9
112. Rada B, Leto TL. Oxidative Innate Immune Defenses by Nox/Duox Family NADPH Oxidases. Egesten A, Schmidt A, Herwald H (eds): Trends in Innate Immunity. Contrib Microbiol. Basel, Karger, 2008, vol 15, pp 164-187
113. Registry of Toxic Effects of Chemical Substances '77, German drug use
114. Santos MS, Meydani SN, Leka L, et al. Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. Am J Clin Nutr 1996; 64:772-7.
115. Schutte BC, McCray PB Jr. [beta]-defensins in lung host defense. Annu Rev Physiol. 2002; 64:709-48